Nicholson KG - Search Results

1

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG. Stephenson I, et al. Among authors: nicholson kg. J Virol. 2006 May;80(10):4962-70. doi: 10.1128/JVI.80.10.4962-4970.2006. J Virol. 2006. PMID: 16641287 Free PMC article. Clinical Trial.

2

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M. Stephenson I, et al. Among authors: nicholson kg. Vaccine. 2003 Apr 2;21(15):1687-93. doi: 10.1016/s0264-410x(02)00632-1. Vaccine. 2003. PMID: 12639491 Clinical Trial.

3

Influenza.

Nicholson KG, Wood JM, Zambon M. Nicholson KG, et al. Lancet. 2003 Nov 22;362(9397):1733-45. doi: 10.1016/S0140-6736(03)14854-4. Lancet. 2003. PMID: 14643124 Free PMC article. Review.

4

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. Nicholson KG, et al. Lancet. 2001 Jun 16;357(9272):1937-43. doi: 10.1016/S0140-6736(00)05066-2. Lancet. 2001. PMID: 11425416 Clinical Trial.

5

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

Stephenson I, Wood JM, Nicholson KG, Zambon MC. Stephenson I, et al. Among authors: nicholson kg. J Med Virol. 2003 Jul;70(3):391-8. doi: 10.1002/jmv.10408. J Med Virol. 2003. PMID: 12767002

6

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.

Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, Bermingham A, Nicholson K, Zambon M. Stephenson I, et al. Clin Infect Dis. 2009 Feb 15;48(4):389-96. doi: 10.1086/596311. Clin Infect Dis. 2009. PMID: 19133796 Free article.

7

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. Stephenson I, et al. Among authors: nicholson kg. Lancet. 2003 Dec 13;362(9400):1959-66. doi: 10.1016/S0140-6736(03)15014-3. Lancet. 2003. PMID: 14683655 Clinical Trial.

8

Confronting the avian influenza threat: vaccine development for a potential pandemic.

Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Stephenson I, et al. Among authors: nicholson kg. Lancet Infect Dis. 2004 Aug;4(8):499-509. doi: 10.1016/S1473-3099(04)01105-3. Lancet Infect Dis. 2004. PMID: 15288823 Free PMC article. Review.

9

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Clark TW, et al. Among authors: nicholson kg. N Engl J Med. 2009 Dec 17;361(25):2424-35. doi: 10.1056/NEJMoa0907650. Epub 2009 Sep 10. N Engl J Med. 2009. PMID: 19745215 Free article. Clinical Trial.

10

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, Mischler R, Zambon MC, Stephenson I. Nicholson KG, et al. Vaccine. 2009 Dec 10;28(1):171-8. doi: 10.1016/j.vaccine.2009.09.103. Epub 2009 Sep 30. Vaccine. 2009. PMID: 19799843 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

180 results

Search Page